Table 3.

Clinical outcomes at the patient and cycle levels by prophylaxis decision

	Under		Correct		Over		p
	%	95% CI	%	95% CI	%	95% CI
Unit of analysis, patient
Neutropenia episodes
CIN grades 1 through 4	41.0%	(32.7%–49.9%)	39.9%	(32.8%–47.4%)	19.7%	(14.4%–26.3%)	<0.001
CIN grades 3 or 4	24.3%	(18.3%–31.6%)	27.4%	(21.3%–34.5%)	12.5%	(8.5%–18.1%)	<0.001
CIN grade 4	12.0%	(8.2%–17.2%)	16.8%	(12.4%–22.3%)	6.4%	(3.9%–10.3%)	<0.001
FN	5.2%	(2.6%–10.0%)	8.0%	(6.1%–10.3%)	2.1%	(1.1%–4.1%)	<0.001
CIN/FN-related hospitalizations	8.0%	(4.8%–12.9%)	7.1%	(5.0%–10.0%)	2.7%	(1.4%–4.9%)	0.001
CIN/FN-related chemotherapy disturbancesa	14.7%	(10.4%–20.5%)	8.8%	(6.4%–12.1%)	7.7%	(4.9%–11.9%)	n.s.
CIN/FN-related composite outcomeb	24.7%	(18.5%–32.2%)	26.0%	(21.2%–31.4%)	13.0%	(9.4%–17.8%)	<0.001
Unit of analysis, cycle
Neutropenia episodes
CIN grades 1 through 4	17.9%	(14.7%–21.7%)	16.0%	(14.3%–17.9%)	8.3%	(6.4%–10.7%)	<0.001
CIN grades 3 or 4	9.5%	(7.2%–12.4%)	9.4%	(8.2%–10.9%)	3.8%	(2.8%–5.3%)	<0.001
CIN grade 4	4.0%	(2.8%–5.8%)	4.8%	(4.0%–5.8%)	1.7%	(1.1%–2.7%)	<0.001
FN	1.6%	(0.9%–2.9%)	1.7%	(1.3%–2.2%)	0.5%	(0.2%–1.1%)	<0.001
CIN/FN-related hospitalizations	2.5%	(1.6%–4.1%)	1.6%	(1.2%–2.2%)	0.6%	(0.3%–1.1%)	<0.001
CIN/FN-related chemotherapy disturbancesa	4.2%	(3.1%–5.7%)	2.4%	(1.9%–3.0%)	2.3%	(1.6%–3.4%)	0.032
CIN/FN-related composite outcomeb	8.6%	(6.7%–11.0%)	7.5%	(6.5%–8.6%)	3.9%	(2.9%–5.3%)	<0.001

^aType of chemotherapy disturbances are not mutually exclusive. Any patient may have experienced more than one type. Measured with 1 cycle lag

^bIncludes any occurrence of CIN grade 4, FN, CIN/FN-related hospitalization, and/or CIN/FIN-related chemotherapy disturbance. CI confidence interval n.s. not significant